CorMedix - CRMD Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRMD shares.
View CRMD analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1-year price targets for CorMedix's shares. Their CRMD share price forecasts range from $13.00 to $16.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 339.9% from the stock's current price.
View analysts price targets for CRMD or view top-rated stocks among Wall Street analysts.

CorMedix's stock was trading at $4.22 on January 1st, 2023. Since then, CRMD shares have decreased by 19.2% and is now trading at $3.41.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our CRMD earnings forecast.

CorMedix will be holding an earnings conference call on Thursday, March 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

CorMedix Inc. (NASDAQ:CRMD) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.01 million. CorMedix had a negative net margin of 31,830.43% and a negative trailing twelve-month return on equity of 48.66%.

ETFMG Treatments Testing and Advancements ETF holds 8,958 shares of CRMD stock, representing 0.18% of its portfolio.

Shares of CorMedix reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), QUALCOMM (QCOM), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Marvell Technology (MRVL).

CorMedix trades on the NASDAQ under the ticker symbol "CRMD."

CorMedix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.41%), Geode Capital Management LLC (0.86%), Bank of Montreal Can (0.70%), Susquehanna International Group LLP (0.00%), Marshall Wace LLP (0.37%) and HBK Sorce Advisory LLC (0.36%). Insiders that own company stock include Alan W Dunton, Elizabeth Masson-Hurlburt, Joseph Todisco, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts and Steven W Lefkowitz.
View institutional ownership trends.

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRMD stock can currently be purchased for approximately $3.41.

CorMedix (NASDAQ:CRMD) has a market capitalization of $140.76 million and generates $190,000.00 in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

CorMedix's mailing address is 300 CONNELL DRIVE SUITE 4200, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cormedix.com. The company can be reached via phone at (908) 517-9500, via email at daniel@lifesciadvisors.com, or via fax at 908-429-4307.